The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug,...

The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug,...


AbbVie Inc and Neurocrine Biosciences, Inc. presented positive additional results from two replicate Phase 3 trials that evaluated the efficacy and safety of elagolix in women with uterine fibroids at the 47th American Association of Gynecologic Laparoscopists Global Congress on Minimally Invasive Gynecology in Las Vegas, Nevada. At month six of the six-month treatment period, elagolix 300mg twice a day in combination with low-dose hormone therapy reduced heavy menstrual bleeding related to uterine fibroids compared to placebo.



from Biotech News